Lpath Inc Cmn A (LPTN) 0.16 $LPTN
Lpath Announces 1-for-14 Reverse Stock Split
PR Newswire - Thu Jun 09, 7:02AM CDT
Lpath, Inc. (NASDAQ: LPTN) announced a 1-for-14 reverse split of the company's issued and outstanding common stock, effective as of 5:00 p.m. EDT on June 10, 2016. Beginning at the opening of trading on June 13, 2016, Lpath's common stock will begin trading on a split adjusted basis, and the number of common shares outstanding will be decreased from approximately 33.1 million pre-split to 2.36 million shares post-split.
LPTN: 0.16 (unch)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 0.60 (unch), SNTA: 0.35 (-0.01), CTIC: 0.43 (-0.01), LPTN: 0.16 (unch)
Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 1.08 (+0.07), UPL: 0.31 (unch), CPLP: 3.04 (-0.06), LPTN: 0.16 (unch)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.44 (-0.07), HTM: 0.80 (-0.02), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 0.47 (-0.04), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
Lpath Reports Favorable Results from Phase 1 Study of Lpathomab
PR Newswire - Tue Apr 19, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of its Phase 1 double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab(TM) in healthy volunteers. Lpathomab was well tolerated at all doses tested, and no serious adverse events or dose limiting toxicities were observed.
LPTN: 0.16 (unch)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 0.16 (unch), OMER: 10.75 (-0.09), ATHX: 2.38 (+0.03), KPTI: 8.53 (-0.60), CUR: 0.33 (-0.01)
Lpath Completes Dosing in the Lpathomab Phase 1 Safety Study
PR Newswire - Mon Feb 01, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of dosing in its Phase 1a double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab(TM) in healthy volunteers. Lpathomab has been well tolerated at all doses tested, and no serious adverse events or dose limiting toxicities have been observed to date.
LPTN: 0.16 (unch)
Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 35.29 (-0.02), VBAY: (), BMY: 72.65 (-0.08), LPTN: 0.16 (unch), OMER: 10.75 (-0.09), CUR: 0.33 (-0.01), CELGZ: 1.46 (-0.04)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.40 (-0.09), GALT: 1.42 (-0.05), ICPT: 150.66 (-3.56), RGLS: 5.27 (-0.07), ABBV: 61.00 (+0.25), LPTN: 0.16 (unch)
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.64 (-0.01), LPTN: 0.16 (unch)
Lpath to Hold Corporate Update Conference Call and Live Webcast on Tuesday, November 17th
PR Newswire - Mon Nov 16, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that the company will host a conference call and live webcast tomorrow, Tuesday, November 17, 2015 beginning at 5:00 p.m. EST/2:00 p.m. PST to provide a corporate update and review data from the Nexus Phase 2 study that evaluated iSONEP(TM) as a treatment for patients with wet age-related macular degeneration. The data from the Nexus study was recently presented at the American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day.
LPTN: 0.16 (unch)
Lpath to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration at the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day
PR Newswire - Thu Nov 05, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that data from the Nexus Phase 2 study of iSONEP(TM) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on Saturday, November 14 at 12:59 p.m. Pacific Time. Presenting the data in an oral presentation will be Thomas Ciulla, M.D., a Nexus investigator and practicing ophthalmologist and retinal surgeon in Indianapolis, IN.
LPTN: 0.16 (unch)
Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 91.49 (-1.00), ATHX: 2.38 (+0.03), ACOR: 27.07 (-0.45), LPTN: 0.16 (unch), OMER: 10.75 (-0.09), CUR: 0.33 (-0.01)
Lpath Appoints Gary Atkinson Interim Chief Executive Officer
PR Newswire - Tue Sep 29, 3:05PM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpath's chief financial officer.
ISIS: 57.56 (-0.28), LPTN: 0.16 (unch)
Lpath Initiates First-in-Human Dosing in Phase 1 Clinical Trial of Lpathomab
PR Newswire - Tue Sep 15, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses.
LPTN: 0.16 (unch)
Polypoidal Choroidal Vasculopathy - Global Clinical Trials Review, H2, 2015
M2 - Mon Sep 14, 5:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vv668j/polypoidal) has announced the addition of the "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" report to their offering. "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" provides an overview of Polypoidal Choroidal Vasculopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Polypoidal Choroidal Vasculopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Top Companies Participating in Polypoidal Choroidal Vasculopathy Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Bayer AG - Regeneron Pharmaceuticals, Inc. - Novartis AG - Hawaii Pacific Health - Pfizer Inc. - OXiGENE, Inc. - Oraya Therapeutics, Inc. - Ophthotech Corp. - Lpath, Inc. Clinical Trial Overview of Top Institutes / Government - Southeast Retina Center - Asan Medical Center - Federal University of Sao Paulo - Hyogo College Of Medicine - Kagawa University - Kyungpook National University - La Fondation Ophtalmologique Adolphe de Rothschild - Manhattan Eye Ear & Throat Hospital - Medizinische Universitat Wien - Nihon University For more information visit http://www.researchandmarkets.com/research/vv668j/polypoidal
OXGN: 0.79 (+0.12), PFE: 35.29 (-0.02), OPHT: 56.33 (+0.17), LPTN: 0.16 (unch), REGN: 372.03 (-9.05), NVS: 78.94 (-1.57)
Lpath Announces Plan to Begin Lpathomab Clinical Trial
PR Newswire - Thu Jul 23, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab(TM). The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.
LPTN: 0.16 (unch)
Kidney Fibrosis - Pipeline Review, H1 2015 - 13 Companies & 19 Drug Profiles
M2 - Wed Jun 10, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhppdp/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Galectin Therapeutics, Inc. - GNI Group Ltd. - Lpath, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - RestorGenex Corporation - Tobira Therapeutics, Inc. Drug Profiles - ANG-3298 - ANG-4011 - BOT-191 - BRN-1889 - cenicriviroc mesylate - CGEN-856 - CT-140 - cysteamine DR - F-351 - Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - GR-MD-02 - ICG-001 - LJ-1888 - Lpathomab - P-007 - P-529 - PBI-4050 - RG-012 - Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis For more information visit http://www.researchandmarkets.com/research/qh...y_fibrosis
RPTP: 5.40 (-0.09), GALT: 1.42 (-0.05), RGLS: 5.27 (-0.07), ABBV: 61.00 (+0.25), TBRA: 10.06 (+0.36), LPTN: 0.16 (unch)
Lpath Announces 1-for-14 Reverse Stock Split
PR Newswire - Thu Jun 09, 7:02AM CDT
Lpath, Inc. (NASDAQ: LPTN) announced a 1-for-14 reverse split of the company's issued and outstanding common stock, effective as of 5:00 p.m. EDT on June 10, 2016. Beginning at the opening of trading on June 13, 2016, Lpath's common stock will begin trading on a split adjusted basis, and the number of common shares outstanding will be decreased from approximately 33.1 million pre-split to 2.36 million shares post-split.
LPTN: 0.16 (unch)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 0.60 (unch), SNTA: 0.35 (-0.01), CTIC: 0.43 (-0.01), LPTN: 0.16 (unch)
Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 1.08 (+0.07), UPL: 0.31 (unch), CPLP: 3.04 (-0.06), LPTN: 0.16 (unch)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.44 (-0.07), HTM: 0.80 (-0.02), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 0.47 (-0.04), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
Lpath Reports Favorable Results from Phase 1 Study of Lpathomab
PR Newswire - Tue Apr 19, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of its Phase 1 double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab(TM) in healthy volunteers. Lpathomab was well tolerated at all doses tested, and no serious adverse events or dose limiting toxicities were observed.
LPTN: 0.16 (unch)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 0.16 (unch), OMER: 10.75 (-0.09), ATHX: 2.38 (+0.03), KPTI: 8.53 (-0.60), CUR: 0.33 (-0.01)
Lpath Completes Dosing in the Lpathomab Phase 1 Safety Study
PR Newswire - Mon Feb 01, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today completion of dosing in its Phase 1a double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab(TM) in healthy volunteers. Lpathomab has been well tolerated at all doses tested, and no serious adverse events or dose limiting toxicities have been observed to date.
LPTN: 0.16 (unch)
Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 35.29 (-0.02), VBAY: (), BMY: 72.65 (-0.08), LPTN: 0.16 (unch), OMER: 10.75 (-0.09), CUR: 0.33 (-0.01), CELGZ: 1.46 (-0.04)
Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 5.40 (-0.09), GALT: 1.42 (-0.05), ICPT: 150.66 (-3.56), RGLS: 5.27 (-0.07), ABBV: 61.00 (+0.25), LPTN: 0.16 (unch)
Diabetic Retinopathy - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/kr3mll/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Diabetic Retinopathy's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Include: - Acucela Inc. - Aerpio Therapeutics, Inc. - Angstrom Pharmaceuticals, Inc. - Antisense Therapeutics Limited - BCN Peptides, S.A. - BioDiem Ltd - Biomar Microbial Technologies - Charlesson LLC. - Crinetics Pharmaceuticals, Inc. - Dimerix Bioscience Pty Ltd - Dynamis Therapeutics, Inc. - EyeGene, Inc. - Foresee Pharmaceuticals, LLC - GTx, Inc. - Icon Bioscience, Inc. - IMMD Inc. - Islet Sciences, Inc. - Kowa Company, Ltd. - LegoChem Biosciences, Inc - Lpath, Inc. - Others (20) For more information visit http://www.researchandmarkets.com/research/kr3mll/diabetic
GTXI: 0.64 (-0.01), LPTN: 0.16 (unch)
Lpath to Hold Corporate Update Conference Call and Live Webcast on Tuesday, November 17th
PR Newswire - Mon Nov 16, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced today that the company will host a conference call and live webcast tomorrow, Tuesday, November 17, 2015 beginning at 5:00 p.m. EST/2:00 p.m. PST to provide a corporate update and review data from the Nexus Phase 2 study that evaluated iSONEP(TM) as a treatment for patients with wet age-related macular degeneration. The data from the Nexus study was recently presented at the American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day.
LPTN: 0.16 (unch)
Lpath to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration at the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day
PR Newswire - Thu Nov 05, 7:00AM CST
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that data from the Nexus Phase 2 study of iSONEP(TM) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on Saturday, November 14 at 12:59 p.m. Pacific Time. Presenting the data in an oral presentation will be Thomas Ciulla, M.D., a Nexus investigator and practicing ophthalmologist and retinal surgeon in Indianapolis, IN.
LPTN: 0.16 (unch)
Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 91.49 (-1.00), ATHX: 2.38 (+0.03), ACOR: 27.07 (-0.45), LPTN: 0.16 (unch), OMER: 10.75 (-0.09), CUR: 0.33 (-0.01)
Lpath Appoints Gary Atkinson Interim Chief Executive Officer
PR Newswire - Tue Sep 29, 3:05PM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpath's chief financial officer.
ISIS: 57.56 (-0.28), LPTN: 0.16 (unch)
Lpath Initiates First-in-Human Dosing in Phase 1 Clinical Trial of Lpathomab
PR Newswire - Tue Sep 15, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses.
LPTN: 0.16 (unch)
Polypoidal Choroidal Vasculopathy - Global Clinical Trials Review, H2, 2015
M2 - Mon Sep 14, 5:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vv668j/polypoidal) has announced the addition of the "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" report to their offering. "Polypoidal Choroidal Vasculopathy Global Clinical Trials Review, H2, 2015" provides an overview of Polypoidal Choroidal Vasculopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Polypoidal Choroidal Vasculopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Top Companies Participating in Polypoidal Choroidal Vasculopathy Therapeutics Clinical Trials - F. Hoffmann-La Roche Ltd. - Bayer AG - Regeneron Pharmaceuticals, Inc. - Novartis AG - Hawaii Pacific Health - Pfizer Inc. - OXiGENE, Inc. - Oraya Therapeutics, Inc. - Ophthotech Corp. - Lpath, Inc. Clinical Trial Overview of Top Institutes / Government - Southeast Retina Center - Asan Medical Center - Federal University of Sao Paulo - Hyogo College Of Medicine - Kagawa University - Kyungpook National University - La Fondation Ophtalmologique Adolphe de Rothschild - Manhattan Eye Ear & Throat Hospital - Medizinische Universitat Wien - Nihon University For more information visit http://www.researchandmarkets.com/research/vv668j/polypoidal
OXGN: 0.79 (+0.12), PFE: 35.29 (-0.02), OPHT: 56.33 (+0.17), LPTN: 0.16 (unch), REGN: 372.03 (-9.05), NVS: 78.94 (-1.57)
Lpath Announces Plan to Begin Lpathomab Clinical Trial
PR Newswire - Thu Jul 23, 7:00AM CDT
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab(TM). The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.
LPTN: 0.16 (unch)
Kidney Fibrosis - Pipeline Review, H1 2015 - 13 Companies & 19 Drug Profiles
M2 - Wed Jun 10, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhppdp/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Galectin Therapeutics, Inc. - GNI Group Ltd. - Lpath, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - RestorGenex Corporation - Tobira Therapeutics, Inc. Drug Profiles - ANG-3298 - ANG-4011 - BOT-191 - BRN-1889 - cenicriviroc mesylate - CGEN-856 - CT-140 - cysteamine DR - F-351 - Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - GR-MD-02 - ICG-001 - LJ-1888 - Lpathomab - P-007 - P-529 - PBI-4050 - RG-012 - Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis For more information visit http://www.researchandmarkets.com/research/qh...y_fibrosis
RPTP: 5.40 (-0.09), GALT: 1.42 (-0.05), RGLS: 5.27 (-0.07), ABBV: 61.00 (+0.25), TBRA: 10.06 (+0.36), LPTN: 0.16 (unch)
